Please login to the form below

Not currently logged in
Email:
Password:

ovarian cancer

This page shows the latest ovarian cancer news and features for those working in and with pharma, biotech and healthcare.

Ovarian Cancer Commitment announced to improve patient care

Ovarian Cancer Commitment announced to improve patient care

The coalition was announced by ENGAGe, ESGO and AstraZeneca in a call to improve ovarian cancer care. ... The OCC is a coalition, collaborating to focus on improving the experience and survival of women diagnosed with ovarian cancer.

Latest news

More from news
Approximately 39 fully matching, plus 185 partially matching documents found.

Latest Intelligence

  • After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

    These T cells are then injected back into the bloodstream with the aim of targeting and killing cancer cells. ... Currently the company is conducting a phase 1 trial for advanced ovarian cancer in a dose escalation trial that will treat four separate

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    That includes potential new approvals for PARP inhibitor Lynparza in prostate and pancreatic cancer to extend its existing use in ovarian and breast cancer. ... in July 2019, which involved 22 plaintiffs who alleged using J&J talc caused them to develop

  • Case study: Ovarian Cancer Action (OCA) Case study: Ovarian Cancer Action (OCA)

    Every rose had a tag with the symptoms of ovarian cancer, Ovarian Cancer Action’s url and #WOCD. ... The charity also lobbied politicians across the UK to support World Ovarian Cancer Day.

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    Reic said the adoption of diagnostics into standard clinical practice has been one of the biggest challenges in Lynparza’s first indication, ovarian cancer – but this must now be replicated in ... First we had ovarian cancer, then breast cancer, and

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... People who have BRCA gene mutations have an

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
Report: Omnichannel advice for the life science industry
In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...